ASIT Biotech – pharmaceutical daily

March 20, 2017 Off

ASIT biotech welcomes new Chairman of the Board

ASIT biotech, a Belgian clinical-stage biopharmaceutical company focused on the research, development and future commercialization of immunotherapy products for the treatment of allergies, has appointed Gerd Zettlmeissl as its new Chairman of the Board, Béatrice De Vos having stood down to focus on new projects.

January 24, 2017 Off

Asit’s Phase II study of dust allergy treatment shows success

By Dino Mustafić

Asit biotech has completed Phase IIa double-blind placebo-controlled clinical study in house dust mite-induced rhinoconjunctivitis.

January 12, 2017 Off

Walloon (Belgium) government funds ASIT Biotech’s food allergies treatment research

By Dino Mustafić

The Walloon (Belgium) government has decided to fund its ASIT Biotech to help develop new drug candidates to treat the main food allergies caused by peanuts, cow’s milk and egg whites.